Cargando…

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling

Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with diabetes. The mechanism underlying the beneficial effect of SGLT2 inhibitors i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durante, William, Behnammanesh, Ghazaleh, Peyton, Kelly J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396183/ https://www.ncbi.nlm.nih.gov/pubmed/34445519 http://dx.doi.org/10.3390/ijms22168786

Ejemplares similares

Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1
por: Behnammanesh, Ghazaleh, et al.
Publicado: (2020)

Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1
por: Peyton, Kelly J., et al.
Publicado: (2022)

Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage
por: Kourtidou, Christodoula, et al.
Publicado: (2023)

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
por: Behnammanesh, Ghazaleh, et al.
Publicado: (2019)

Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney Function
por: Van Raalte, Daniel H., et al.
Publicado: (2022)

Harms and benefits of sodium-glucose co-transporter 2 inhibitors
por: Chesterman, Thomas, et al.
Publicado: (2020)

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
por: Erythropoulou-Kaltsidou, Anastasia, et al.
Publicado: (2019)

Sodium-glucose co-transporter 2 inhibitors beyond diabetes
por: Williams, Dimity L, et al.
Publicado: (2022)

Sodium glucose co-transport 2 inhibitors for gout treatment
por: Somagutta, Manoj Kumar Reddy, et al.
Publicado: (2022)

Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Jing, Yuling, et al.
Publicado: (2022)

Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment
por: D'Onofrio, Nunzia, et al.
Publicado: (2021)

Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Pancreatic β-Cell Mass and Function
por: Nakamura, Akinobu
Publicado: (2022)

The Evolution of Sodium-Glucose Co-Transporter-2 Inhibitors in Heart Failure
por: Fadiran, Olusayo, et al.
Publicado: (2021)

Impact of Sodium–Glucose Co-Transporter 2 Inhibitors on Cardiac Protection
por: Wu, Victor Chien-Chia, et al.
Publicado: (2021)

Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
por: Lahnwong, Sarayut, et al.
Publicado: (2018)

Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
por: Ye, Yangli, et al.
Publicado: (2019)

Sodium glucose co transporter 2 inhibitors and Ramadan: Another string to the bow
por: Kelwade, Jayant, et al.
Publicado: (2014)

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
por: Singh, Awadhesh Kumar
Publicado: (2015)

Sodium glucose co-transporter inhibitors – A new class of old drugs
por: Malhotra, Aneeta, et al.
Publicado: (2015)

Sodium glucose co-transporter-2 inhibitor: Patient safety and clinical importance
por: Senthilkumaran, Subramanian, et al.
Publicado: (2017)

Sodium-Glucose Co-transporter 2 Inhibitor: The Magic Bullet for Obesity in Diabetes?
por: Seo, Ji A
Publicado: (2018)

Sodium Glucose Co-transporter-2 Inhibitor: Benefits beyond Glycemic Control
por: Baruah, Manash Pratim, et al.
Publicado: (2019)

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
por: Zeng, Qingchun, et al.
Publicado: (2021)

Sodium-Glucose Co-transporter-2 Inhibitor-Induced Pruritus: Itching for Answers
por: Ali, Kabeer, et al.
Publicado: (2021)

Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
por: Liang, Bo, et al.
Publicado: (2022)

Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors
por: Dabravolski, Siarhei A., et al.
Publicado: (2022)

Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
por: Prandi, Francesca Romana, et al.
Publicado: (2022)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
por: Shao, Qingmiao, et al.
Publicado: (2019)

Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma
por: Kuang, Haoyu, et al.
Publicado: (2017)

Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
por: Hoehlschen, Julia, et al.
Publicado: (2023)

A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors
por: Niazi, Asfandyar Khan, et al.
Publicado: (2010)

Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
por: Scheen, André J.
Publicado: (2014)

Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use
por: Melnick, Stephen, et al.
Publicado: (2018)

Observational research on sodium glucose co‐transporter‐2 inhibitors: A real breakthrough?
por: Raschi, Emanuel, et al.
Publicado: (2018)

Euglycemic diabetic ketoacidosis by sodium glucose co-transporter inhibitors: Real but preventable concern
por: Raut, Monish S, et al.
Publicado: (2017)

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential
por: Brito, Dulce, et al.
Publicado: (2020)

Sodium-glucose co-transporter-2 inhibitors: A cardiovascular outcome trial analysis
por: Suvarna, Viraj Ramesh
Publicado: (2021)

Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin
por: Ryan, Rebecca, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_22oc21oo1v9fh57ti30maq6qmn